Furthermore, glial fibrillary acidic protein (GFAP), a proposed marker for axonal damage35, has been detected in nerve biopsies in patients with type 2 diabetes and controls36, and elevated serum levels of GFAP were found to correlate to reduced nerve action potentials and disease severity in chronic neuropathies37. This evidence concerns the gene GFAP and type 2 diabetes mellitus.